SCHEMBL5358801

SCHEMBL5358801

Cc1[nH]c(C=C2C(=O)Nc3ccc(Br)c(C)c32)c(Br)c1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.53
RET P07949 7/20 0.41
PDGFRB P09619 9/20 0.40
FGFR1 P11362 7/20 0.40
ALK Q9UM73 4/20 0.39
FLT3 P36888 4/20 0.36
AURKA O14965 2/20 0.36
FLT1 P17948 2/20 0.36
MAP4K2 Q12851 2/20 0.36
STK3 Q13188 2/20 0.36
AURKB Q96GD4 2/20 0.36
PDPK1 O15530 2/20 0.36
GAK O14976 1/20 0.36
RPS6KA5 O75582 1/20 0.36
RPS6KA4 O75676 1/20 0.36
LATS1 O95835 1/20 0.36
CSNK2A2 P19784 1/20 0.36
MAP2K2 P36507 1/20 0.36
ZAP70 P43403 1/20 0.36
MAP2K1 Q02750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367053 0.83 PDGFRB (0.50) KDRRETPDGFRBFGFR1ALK
SCHEMBL5366277 0.81 RET (0.64) KDRRETPDGFRBFGFR1ALK
SCHEMBL7138166 0.79 KDR (0.44) KDRRETPDGFRBFGFR1ALK
SCHEMBL5368918 0.77 PDGFRB (0.66) KDRRETPDGFRBFGFR1ALK
SCHEMBL7134014 0.77 RET (0.48) RETPDGFRBPLK4CDK1EGFR
SCHEMBL5377025 0.77 RET (0.54) KDRRETPDGFRBEGFR
SCHEMBL5365192 0.77 RET (0.40) KDRRETPDGFRBFGFR1ALK
SCHEMBL5999769 0.76 KDR (0.82) KDRRETPDGFRBFGFR1ALK
SCHEMBL5999773 0.76 KDR (0.82) KDRRETPDGFRBFGFR1ALK
SCHEMBL7132935 0.75 MEN1 (0.56) KDRRETPDGFRBFLT3PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK KDR 239/4885RET 283/4885PDGFRB 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.